have reported that 7 of 79 patients with relapsed/refractory B-ALL who received CAR-T therapy targeting CD19 or CD19/CD22 experienced severe ICANS, among whom six received systemic steroids as first-line therapy. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.